ArticleJournal of bone oncology2025

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors.

Mingchuan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.